Sustained Control of Serpiginous Choroiditis with the Fluocinolone Acetonide 0.18 mg Intravitreal Implant.

IF 0.7 Q4 OPHTHALMOLOGY Case Reports in Ophthalmological Medicine Pub Date : 2022-01-01 DOI:10.1155/2022/3962221
Yousuf Siddiqui, Olufemi E Adams, Michael A Simmons, Justin Yamanuha, Dara D Koozekanani
{"title":"Sustained Control of Serpiginous Choroiditis with the Fluocinolone Acetonide 0.18 mg Intravitreal Implant.","authors":"Yousuf Siddiqui,&nbsp;Olufemi E Adams,&nbsp;Michael A Simmons,&nbsp;Justin Yamanuha,&nbsp;Dara D Koozekanani","doi":"10.1155/2022/3962221","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To describe an alternative treatment for a patient with serpiginous choroiditis (SC) who was not tolerant to systemic therapies.</p><p><strong>Methods: </strong>Case report of a patient with serpiginous choroiditis with their clinical course followed with ophthalmic examinations and multimodal imaging overtime. <i>Patients and Results</i>. A 57-year-old female with serpiginous choroiditis was treated for seven years with numerous therapies including systemic steroids, immunosuppressive agents, and repeated dexamethasone intravitreal implants. The patient was intolerant of systemic therapies and would flare if dexamethasone injections were performed less frequently than every 8 weeks, making a viable long-term treatment plan problematic. Following one injection of the fluocinolone acetonide 0.18 mg intravitreal implant, she has experienced sustained control for 20 months. <i>Discussion and Conclusions</i>. Real-world treatment of SC is complex as long-term control is necessary, and associated side effects of the therapies provided may limit sustained use. The fluocinolone acetonide implant lasts 36 months and may be an alternative long-term management option, especially in the setting of systemic medication intolerance for some patients with SC.</p>","PeriodicalId":9603,"journal":{"name":"Case Reports in Ophthalmological Medicine","volume":"2022 ","pages":"3962221"},"PeriodicalIF":0.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794418/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Ophthalmological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/3962221","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To describe an alternative treatment for a patient with serpiginous choroiditis (SC) who was not tolerant to systemic therapies.

Methods: Case report of a patient with serpiginous choroiditis with their clinical course followed with ophthalmic examinations and multimodal imaging overtime. Patients and Results. A 57-year-old female with serpiginous choroiditis was treated for seven years with numerous therapies including systemic steroids, immunosuppressive agents, and repeated dexamethasone intravitreal implants. The patient was intolerant of systemic therapies and would flare if dexamethasone injections were performed less frequently than every 8 weeks, making a viable long-term treatment plan problematic. Following one injection of the fluocinolone acetonide 0.18 mg intravitreal implant, she has experienced sustained control for 20 months. Discussion and Conclusions. Real-world treatment of SC is complex as long-term control is necessary, and associated side effects of the therapies provided may limit sustained use. The fluocinolone acetonide implant lasts 36 months and may be an alternative long-term management option, especially in the setting of systemic medication intolerance for some patients with SC.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
0.18 mg醋酸氟西诺酮玻璃体内植入对蛇形脉络膜炎的持续控制。
目的:描述对全身治疗不耐受的蛇形脉络膜炎(SC)患者的替代治疗。方法:报告1例蛇形脉络膜炎患者的临床病程,并进行眼科检查和多模态影像学检查。患者和结果。一名患有蛇形脉络膜炎的57岁女性患者接受了7年的治疗,包括全身类固醇、免疫抑制剂和反复地塞米松玻璃体内植入物。患者对全身治疗不耐受,如果地塞米松注射频率低于每8周一次,则会发作,使可行的长期治疗计划成为问题。在一次注射0.18 mg氟西诺酮醋酸酯玻璃体内植入物后,她经历了20个月的持续控制。讨论和结论。SC的实际治疗是复杂的,因为长期控制是必要的,所提供的治疗的相关副作用可能限制持续使用。氟西诺酮植入物持续36个月,可能是另一种长期管理选择,特别是在一些SC患者的全身药物不耐受的情况下。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
38
审稿时长
14 weeks
期刊最新文献
Semaglutide Inducing Resolution of Proliferative Diabetic Retinopathy: A Case Report. Quantification of Goldmann Visual Fields During Resolution of Traumatic Optic Neuropathy. A Case of Pediatric Myopia Complicated by Vitreous Cyst: A Unique Ophthalmic Challenge. Optic Neuropathy AFG3L2 Related in a Patient Affected by Congenital Stationary Night Blindness. Sudden Visual Loss After Vitreoretinal Surgery: A Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1